Valneva
phase month schedule showed high immunogenicity rates after completion of primary vaccination series ranged from to in highest dose | Valneva
Company
Deck Type
IPO
Sector
Industry
Deck date
April 2021
Slide
13 of 41
Related slides by other companies
ATAI
Investor Presentation
March 2023
changes in beta power from dose to hour post dose placebo low doses high doses no significant change significant increase preliminary data subject to change phase dose dependent frontal was demonstrated providing evidence of target engagement and mechanism of action a a | ATAI
Fusion Pharmaceuticals
Investor Presentation
August 2023
future milestones by program | Fusion Pharmaceuticals
Apollomics
SPAC
September 2022
| Apollomics
AngloAmerican
ESG
May 2022
attractive high margin growth options | AngloAmerican
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io